LIVECAST Markets Briefs Calendar Search

Research

Macro Politics Crypto Prediction Markets Disclosure Wire News Archive

LIVECAST Markets

Menu

Home LIVECAST Markets Briefs Calendar Search Macro Politics Crypto Prediction Markets Disclosure Wire News Archive

Live News REGULATION L impact Jul 28, 2026, 11:44 AM UTC

REPL -21% premarket after FDA headlines

REPL -21% premarket after FDA headlines

SquawkNews Newsroom

REPL -21% premarket after FDA headlines

Use this page

Share or save this market-moving headline as a permanent SquawkNews URL. The live feed continues at /news.

Open live news feed Browse news archive Browse news categories Search related coverage

Related tickers

REPL

Related stories

LAB standard Biotools - enters termination, waiver and release agreement with Illumina on July 24, 2026 - SEC filing - Receives about $30M i LAB standard Biotools - enters termination, waiver and release agreement with Illumina on July 24, 2026 - SEC filing - Receives about $30M in cash from Illumina for waiver and rele L impact | REGULATION | Jul 28, 2026, 12:22 PM UTC CRBP Corbus Pharmaceuticals announces FDA clearance to initiate tempo-1 registrational study of crb-701 in patients with 2l oropharyngeal ca CRBP Corbus Pharmaceuticals announces FDA clearance to initiate tempo-1 registrational study of crb-701 in patients with 2l oropharyngeal cancer Corbus Pharmaceuticals announces FD L impact | REGULATION | Jul 28, 2026, 12:00 PM UTC AIFF - Firefly Neuroscience (NASDAQ: AIFF) and Next Health Launch Precision Cognitive Health Initiative as FDA Advisory Committee’s Recommen AIFF - Firefly Neuroscience (NASDAQ: AIFF) and Next Health Launch Precision Cognitive Health Initiative as FDA Advisory Committee’s Recommendation Backs Broader Access to Key Neuro M impact | REGULATION | Jul 28, 2026, 11:50 AM UTC CMND - Clearmind Medicine Successfully Completes Part A of its FDA Regulated Phase I/II Trial - Click For Release CMND - Clearmind Medicine Successfully Completes Part A of its FDA Regulated Phase I/II Trial - Click For Release L impact | REGULATION | Jul 28, 2026, 11:47 AM UTC Dyne Therapeutics receives FDA clearance to initiate DYNE-302 trial Dyne Therapeutics... L impact | REGULATION | Jul 28, 2026, 11:41 AM UTC REPL FDA staff reviewers Flag concerns regarding Replimune's cancer drug trial ahead of July 30 advisory committee meeting - briefing docs REPL FDA staff reviewers Flag concerns regarding Replimune's cancer drug trial ahead of July 30 advisory committee meeting - briefing docs L impact | REGULATION | Jul 28, 2026, 11:41 AM UTC

SQUAWK/NEWS

Real-time financial news agency for traders. Market-relevant headlines on screen and read aloud through the LiveCast audio squawk.

Pro plan coming — join the list.

Product

LiveCast
Live Markets
Session Briefs
Calendar
Search

Research

Macro
Politics
Crypto
Prediction Markets
Disclosure Wire
News Archive

For Traders

Market Movers
US Stocks
News for Traders
How to Trade News
What Is a Squawk
Policy Calendar

Company

About
Why SquawkNews
Newsroom
Editorial Standards
Corrections
Contact

Legal

Privacy Policy
Terms of Use

© 2026 SquawkNews robots / sitemap Privacy Policy SquawkNews publishes factual market information and context. It is not investment advice and does not provide trade recommendations.

We use analytics (GA4, Clarity, PostHog) to improve the product. Privacy Policy